IL-17-Expressing CD4+and CD8+T Lymphocytes in Human Toxoplasmosis

Silva, Jéssica Líver Alves; Rezende-Oliveira, Karine; Silva, Marcos; Gómez-Hernández, César; Peghini, Bethânea Crema; Silva, Neide Maria; Mineo, José Roberto; Júnior, Virmondes Rodrigues

doi:10.1155/2014/573825

Cited by 16 publications

(20 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is important to consider that IL-17 is a classic example of a “double-edged sword” that is capable of inducing a protective immune response to pathogen infection, while also having the ability to contribute to autoimmune disorders (Curtis and Way, 2009 ; Korn et al, 2009 ). IL-17-expressing CD4+ and CD8+ T-lymphocytes play significant roles in the inflammatory response to Toxoplasma gondii and Trypanosoma cruzi , thus blocking parasite invasion or replication in humans (Miyazaki et al, 2010 ; Silva et al, 2014 ). The importance of Th17 cells was demonstrated in their ability to control the development of such intracellular protozoa and promote the differentiation of activated macrophages and neutrophils, thereby supporting the inflammatory response.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of a Major Surface Antigen of Babesia microti Merozoites as a Vaccine Candidate against Babesia Infection

Man¹,

Fu²,

Guan³

et al. 2017

Front. Microbiol.

View full text Add to dashboard Cite

Babesia species are tick-borne intraerythrocytic protozoa that cause babesiosis in humans worldwide. No vaccine has yet proven effective against Babesia infection. Surface antigens of merozoites are involved in the invasion of erythrocytes by Babesia. Surface antigens may be presented by both babesial sporozoites and merozoites and provide a general target for antibody-mediated inhibition of erythrocyte invasion. Here we evaluated a major surface antigen of B. microti merozoites, BMSA, as a potential vaccine to prevent babesiosis. Our data indicated that bmsa is transcribed during different phases, including ring form, amoeboid form, and merozoites, and that its expression is significantly increased in mature merozoites. The protein was found to be located in the membrane of B. microti and in the cytoplasm of infected erythrocytes. The immune response induced by BMSA had a significant inhibitory effect on parasite invasion of the host erythrocytes (83.3% inhibition of invasion) and parasite growth in vivo. The levels of parasitemia significantly decreased after BMSA vaccination when mice were infected with babesia parasite. Importantly, protective immunity was significantly related to the upregulation of the Th17 cytokine interleukin-17, the Th1 cytokine interleukin-12p70 and the Th2 cytokines, such as interleukin-4, -6, and -10. Ingenuity Pathway Analysis indicated that interleukin-17 facilitated the secretion of Th2 cytokines, such as interleukin-10, -4, and -6, thereby inducing a predominately Th2 protective immune response and promoting the expression a high level of special IgG1 against Babesia infection. Further, an anti-BMSA monoclonal antibody successfully protected NOD/SCID mice from a challenge with B. microti. Taken together, our results indicated that BMSA induces a protective immune response against Babesia infection and may serve as a potential vaccine.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of a Major Surface Antigen of Babesia microti Merozoites as a Vaccine Candidate against Babesia Infection

Man¹,

Fu²,

Guan³

et al. 2017

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…An unexpected observation in our mouse vaccination studies was the induction of a substantial subset of CD8 T cells staining positive for IL-17. These have occasionally been observed in various fungal and protozoan disease states ( 40 – 42 ) and were found in one study within tuberculosis-induced pleural infusions ( 43 ). As yet, it is unclear whether their presence is beneficial.…”

Section: Discussionmentioning

confidence: 80%

GI-19007, a Novel Saccharomyces cerevisiae-Based Therapeutic Vaccine against Tuberculosis

King

Shanley

Guo

et al. 2017

Clin Vaccine Immunol

View full text Add to dashboard Cite

As yet, very few vaccine candidates with activity in animals against Mycobacterium tuberculosis infection have been tested as therapeutic postexposure vaccines. We recently described two pools of mycobacterial proteins with this activity, and here we describe further studies in which four of these proteins (Rv1738, Rv2032, Rv3130, and Rv3841) were generated as a fusion polypeptide and then delivered in a novel yeast-based platform (Tarmogen) which itself has immunostimulatory properties, including activation of Toll-like receptors. This platform can deliver antigens into both the class I and class II antigen presentation pathways and stimulate strong Th1 and Th17 responses. In mice this fusion vaccine, designated GI-19007, was immunogenic and elicited strong gamma interferon (IFN-γ) and interleukin-17 (IL-17) responses; despite this, they displayed minimal prophylactic activity in mice that were subsequently infected with a virulent clinical strain. In contrast, in a therapeutic model in the guinea pig, GI-19007 significantly reduced the lung bacterial load and reduced lung pathology, particularly in terms of secondary lesion development, while significantly improving survival in one-third of these animals. In further studies in which guinea pigs were vaccinated with BCG before challenge, therapeutic vaccination with GI-19007 initially improved survival versus that of animals given BCG alone, although this protective effect was gradually lost at around 400 days after challenge. Given its apparent ability to substantially limit bacterial dissemination within and from the lungs, GI-19007 potentially can be used to limit lung damage as well as facilitating chemotherapeutic regimens in infected individuals.

show abstract

“…Interleukin-17A plays a key role in anti-microbial and anti-fungal defence by inducing cytokines, chemokines that affect neutrophil activation [ 36 , 37 ]. Some studies have demonstrated that IL-17 cells mediate host defences against Chagas disease, mucocutaneous leishmaniasis, alveolar disease and opportunistic infections such as pneumocystosis, toxoplasmosis and cryptosporidiosis [ 38 – 42 ]. IL-17 is also involved in the pathogenesis of autoimmune diseases and transplant rejection reactions of organs [ 37 ].…”

Section: Discussionmentioning

confidence: 99%

Changes in the immune system in experimental acanthamoebiasis in immunocompetent and immunosuppressed hosts

et al. 2018

View full text Add to dashboard Cite

BackgroundAcanthamoebiasis is most often found in patients with immune deficiency, with infections facilitated by the intake of immunosuppressive drugs. The host immune response to Acanthamoeba spp. infection is poorly understood. Thus, in this study, we aimed to examine the course of Acanthamoeba spp. infection taking into account the host’s immunological status, including assessment of the hematological parameters, cytokine analysis, immunophenotypic changes in spleen populations, and histological spleen changes, which could help clarify some aspects of the immune response to acanthamoebiasis. In our experimental study, we used Acanthamoeba strain AM 22 isolated from the bronchoaspirate of a patient with acute myeloid leukaemia (AML) and atypical pneumonia symptoms.ResultsAcanthamoeba spp. affected the hematological parameters in immunocompetent and immunosuppressed mice and induced a change in spleen weight during infection. Moreover, analysis of anti-inflammatory (IL-4 and IL-10) and pro-inflammatory (IL-17A and IFN-γ) cytokines produced by splenocytes stimulated with concanavalin A demonstrated that Acanthamoeba spp. induced a selective Th1, Th2 and Th17 response at later stages of the infection in immunocompetent hosts. In the case of hosts with low immunity, Acanthamoeba elicited robust Th1 cell-mediated immunity without the participation of Th17. We observed suppression of CD8+ and CD4+ T lymphocytes and CD3+CD4-CD8- double-negative (DN) T lymphocyte populations in the beginning, and in the case of CD3+/CD4+/CD8+ double-positive (DP) T cells in the final phase of Acanthamoeba spp. infection in hosts with low immunity. Also, CD4+T lymphocytes and CD3+/CD4+ and CD3+/CD8+ lymphocyte counts during each stage of acanthamoebiasis were shown to be upregulated.ConclusionsWe demonstrated that analysis of the immune response and pathogenesis mechanisms of clinical isolates of Acanthamoeba spp. in an animal model not only has purely cognitive significance but above all, may help in the development of effective methods of pharmacological therapy especially in patients with low immunity.

show abstract

IL-17-Expressing CD4⁺and CD8⁺T Lymphocytes in Human Toxoplasmosis

Cited by 16 publications

References 22 publications

Evaluation of a Major Surface Antigen of Babesia microti Merozoites as a Vaccine Candidate against Babesia Infection

Evaluation of a Major Surface Antigen of Babesia microti Merozoites as a Vaccine Candidate against Babesia Infection

GI-19007, a Novel Saccharomyces cerevisiae-Based Therapeutic Vaccine against Tuberculosis

Changes in the immune system in experimental acanthamoebiasis in immunocompetent and immunosuppressed hosts

Contact Info

Product

Resources

About